Onena Medicines

Onena Medicines is a biopharmaceutical company leveraging an AI-centric approach to discover and develop innovative biopharmaceuticals targeting the treatment of cancer and rare diseases. The company's proprietary pipeline consists of first-in-class antibody medicines designed to combat recurrent and metastatic cancers, as well as select rare diseases. Onena's unique focus lies in neutralizing a distinct class of secreted growth factors, known as Dual SMAD Inhibiting Proteins (DSIPs), which play a crucial role in programming cancer cells to resist conventional treatments. Through its AI-centric antibody drug discovery platform, Onena has demonstrated an ability to rapidly generate anti-DSIP neutralizing antibodies, including the lead candidate OMED-101. This promising antibody has shown broad efficacy against breast, colorectal, and brain cancers in preclinical studies without observable toxicities. Founded in 2019 and headquartered in Switzerland, Onena Medicines recently secured a significant €1.70M grant investment at 31 October 2023, with funding provided by CDTI and Eurostars. With a focus on advancing multiple neutralizing DSIP antibody drugs into clinical development within the next three years, Onena Medicines demonstrates both innovative potential and promising investment opportunities in the biotechnology and healthcare sectors.